Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

793
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
793
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

856
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
856
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

711
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
711
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

909
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

1.0K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV: A Chronic Condition.

Journal of insurance medicine (New York, N.Y.)·2016
Same author

Infant mortality: an insured population perspective.

Journal of insurance medicine (New York, N.Y.)·2012
Same author

Omental infarction: an unusual cause of abdominal pain.

Journal of insurance medicine (New York, N.Y.)·2010
Same author

Pediatric overweight: a weighty mortality concern.

Journal of insurance medicine (New York, N.Y.)·2009
Same journal

Creating Evidence-Based Ratings and Life Expectancies Medical Impairments.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

The Smoking Dilemma: A Technical Deep Dive.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Biological Clocks: Ready for Prime Time?

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Identifying Benzodiazepine Abuse: A Report of 3 Cases.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Between Fear and Adoption: The AI Paradox in Medico-Legal Practice Among National Insurance Physicians.

Journal of insurance medicine (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Apical hypertrophic cardiomyopathy--a benign condition?

Daniel D Zimmerman, Therese Bransted, Joy Geiger

    Journal of Insurance Medicine (New York, N.Y.)
    |March 31, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Apical hypertrophic cardiomyopathy (ApHCM) is often considered benign, but new research reveals significant patient variability. This review explores current understanding and risk stratification for ApHCM.

    More Related Videos

    An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
    06:02

    An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

    Published on: November 2, 2020

    6.3K
    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
    14:39

    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

    Published on: April 21, 2014

    18.1K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
    03:45

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

    Published on: August 8, 2022

    4.4K
    An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
    06:02

    An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

    Published on: November 2, 2020

    6.3K
    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
    14:39

    Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

    Published on: April 21, 2014

    18.1K

    Area of Science:

    • Cardiology
    • Genetics
    • Internal Medicine

    Background:

    • Apical hypertrophic cardiomyopathy (ApHCM) is a variant of hypertrophic cardiomyopathy (HCM).
    • Historically, ApHCM has been perceived as a benign condition.
    • Emerging evidence suggests significant heterogeneity and potential for non-benign outcomes in ApHCM patients.

    Purpose of the Study:

    • To review the current understanding of ApHCM.
    • To present a case study illustrating ApHCM.
    • To establish a framework for risk stratification in ApHCM.

    Main Methods:

    • Literature review of recent publications on ApHCM.
    • Case presentation analysis.
    • Development of a risk stratification model.

    Main Results:

    • ApHCM exhibits considerable heterogeneity among patients.
    • The condition is not uniformly benign.
    • A need for individualized risk assessment is highlighted.

    Conclusions:

    • ApHCM requires a nuanced approach beyond its traditional benign classification.
    • Risk stratification is essential for managing ApHCM patients.
    • Further research is needed to refine understanding and management strategies.